Description: Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Home Page: www.bio-techne.com
614 McKinley Place N.E.
Minneapolis,
MN
55413
United States
Phone:
612 379 8854
Officers
| Name | Title |
|---|---|
| Mr. Kim Kelderman | CEO, President & Director |
| Mr. James T. Hippel CPA | Executive VP of Finance & CFO |
| Mr. Shane Bohnen | Senior VP, General Counsel, Corporate Secretary & Chief Sustainability Officer |
| Mr. William A. Geist | President of Protein Sciences Segment |
| Dr. Matthew F. McManus M.D., MBA, Ph.D. | President of Diagnostics & Genomics |
| Dr. Gary J. Latham Ph.D. | VP & CTO |
| Mr. David Clair C.F.A. | Senior Director of Investor Relations & Corporate Development |
| Mr. Gerry Andros | Vice President of Sales and Marketing |
| Mr. Martin Wirtz | Senior Vice President of Strategy & Corporate Development |
| Ms. Cheryl Bethune | Senior VP & Chief Human Resources Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 38.61 |
|---|---|
| Trailing PE: | 76.6667 |
| Price-to-Book MRQ: | 5.4264 |
| Price-to-Sales TTM: | 9.5329 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 3100 |